Lys79
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys79  -  EFTU (human)

Site Information
TLtAAITkILAEGGG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 459170

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:
leukemia ( 2 , 4 , 5 , 6 ) , chronic myelogenous leukemia ( 2 ) , liver cancer ( 10 ) , hepatocellular carcinoma ( 10 )
Relevant cell line - cell type - tissue:

References 

1

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

2

Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

4

Gu T (2005) CST Curation Set: 1006; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

5

Gu T (2005) CST Curation Set: 1007; Year: 2005; Biosample/Treatment: cell line, NB-4/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

6

Gu T (2005) CST Curation Set: 1008; Year: 2005; Biosample1/Treatment/Isotope: cell line, SIL-ALL/none/L, Biosample2/Treatment/Isotope: cell line, SIL-ALL/none/H; Disease: acute lymphocytic leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

7

Li Y (2005) CST Curation Set: 966; Year: 2005; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

8

Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

9

Gu T (2005) CST Curation Set: 958; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

10

Mitchell J (2005) CST Curation Set: 870; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info